Cartrade Tech launches AI-powered transaction tool – SuperDost

Cartrade Tech launches AI-powered transaction tool – SuperDost


Cartrade Tech announced the launch of SuperDost: an AI-powered transaction tool designed to power instant transactions between high-intent buyers and sellers for Automobiles and Used Products.

SuperDost is a live AI Agent which operationalizes the ‘Matchmaker’ strategy by leveraging the combined scale and proprietary data of over 85 million unique monthly visitors across OLX India and CarWale to drive
real-time and Instant, high-intent transactions between buyers and sellers for Automobiles and Used Products.

SuperDost is designed for instant, intelligent matchmaking at scale, bringing together the Company’s Consumers, Dealers and Partners across Automobiles and Used Products within a unified AI-powered interface. It Real-Time connects the most relevant, high-intent buyers and sellers across the platforms.

 

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Mar 04 2026 | 12:16 PM IST



Source link

Cartrade Tech launches AI-powered transaction tool – SuperDost

Silver Touch Technologies secures project from CIMR, New Delhi


To design and develop website and digital platform

Silver Touch Technologies has been awarded the project for designing and development of the website and digital platform for the Centre for Integrative Medicine & Research (CIMR), AIIMS New Delhi.

CIMR is envisioned as a premier national centre dedicated to the convergence of contemporary medicine with Indias traditional systems of healthcare, fostering interdisciplinary research, clinical integration, and evidence-based integrative medical practices.

The digital platform will enable:
h – Structured dissemination of research outcomes
h – Transparent publication of clinical studies and data
h – Seamless stakeholder engagement (researchers, clinicians, students, policymakers)
h – Secure digital governance of medical knowledge assets

 

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Mar 04 2026 | 11:16 AM IST



Source link

Natco Pharma shares rise 3% in weak mkt on launching generic Pomalyst in US

Natco Pharma shares rise 3% in weak mkt on launching generic Pomalyst in US



Natco Pharma shares rose 3.5 per cent in trade on the BSE, logging an intra-day high at ₹990 per share. At 9:55 AM, Natco Pharma’s share price was trading 2.86 per cent higher at ₹983.8. In comparison, Nifty was down 2.02 per cent at 78,616.07. 

 


The buying on the counter came after the company, along with Breckenridge Pharmaceutical, launched Pomalidomide Capsules, a generic version of Pomalyst by Celgene, in the US market. 

 


In an exchange filing, Natco said the product is indicated for adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have shown disease progression during or within 60 days of the last treatment. The drug is also approved for AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy, and for HIV-negative adult patients with Kaposi sarcoma.

 
 


The company said pomalidomide capsules will be available in 1 mg, 2 mg, 3 mg and 4 mg strengths and will be distributed primarily through specialty pharmacies and clinics.

 


Natco said the reference product had estimated US sales of $3.2 billion for the 12 months ended September 2025, citing industry sales data. The company also said it believes, based on information made available by the US Food and Drug Administration (FDA), that it has 180 days of shared exclusivity.

 


“We are pleased to launch Pomalidomide Capsules in the U.S.; this further strengthens our oncology and specialty portfolio in the U.S.,” said Rajeev Nannapaneni, Vice Chairman and CEO of Natco Pharma, according to the release.

 


Breckenridge said it is supporting the launch with copay assistance for eligible patients to help reduce treatment delays and maintain continuity of care.

 


That apart, in Q3FY26, Natco Pharma reported a net profit of ₹151.3 crore, as compared to ₹132.4 crore. Its revenue from operations stood at ₹705.4 crore as compared to ₹651.1 crore year-on-year (Y-o-Y).

 


Natco Pharma, headquartered at Hyderabad, India, develops, manufactures, and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients, and crop protection products. The company is research and development (R&D) oriented, and a science-driven, leading Oncology player in the targeted therapies of the domestic market, and focuses on limited competition molecules in the US.



Source link

Cartrade Tech launches AI-powered transaction tool – SuperDost

Newgen Software Tech arm secures $1.49 million deal with Caribbean based insurance company


Newgen Software Technologies announced that its material subsidiary, Newgen Software Inc, has entered into a Master Service Agreement with a Caribbean-based insurance company for a total contract value of $1,495,000 (approximately Rs 13.77 crore).

According to an exchange filing, the overseas customers name has been withheld due to confidentiality reasons. The scope of the order includes the supply, installation and implementation of the NewgenONE Digital Transformation Platform. The contract covers licensing, implementation, and annual maintenance and support services. The project is scheduled to be executed over a period of three years.

The company clarified that none of its promoters or promoter group entities have any interest in the awarding authority. It also stated that the contract does not qualify as a related-party transaction under applicable regulatory norms.

 

Newgen Software Technologies is a global software company and is engaged in the business of software product development, including designing and delivering end-to-end software solutions covering the entire spectrum of software services from workflow automation to document management to imaging.

The companys consolidated net profit declined 23.16% to Rs 62.81 crore on 0.13% fall in revenue from operations to Rs 400.27 crore in Q3 FY26 over Q2 FY26. On a year on year (YoY) basis, the companys consolidated net profit declined 29.43% while revenue from operations jumped 5.03% in Q3 FY26.

The counter dropped 4.13% to Rs 488.10 on the BSE.

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Mar 04 2026 | 8:04 AM IST



Source link

Motilal Oswal sector of the week: Plastic pipes; top bets, target here

Motilal Oswal sector of the week: Plastic pipes; top bets, target here



India’s plastic pipes industry appears to be approaching a structural inflexion point after navigating several quarters of pricing volatility, margin pressure, and uneven demand. The prolonged correction in PVC prices, which fell nearly 19 per cent during CY25 amid aggressive low-cost imports and weak domestic consumption, now shows signs of reversal. Global supply rationalisation, policy changes impacting export competitiveness, and improving domestic demand dynamics are collectively restoring pricing stability, a key prerequisite for margin normalisation across the sector. 

 


Industry growth remained in the high single digits during the first nine months of FY26, supported primarily by resilient urban plumbing demand even as agricultural consumption and government spending remained subdued. Demand from real estate-linked plumbing applications in Tier-1 and Tier-2 cities continued to outperform, allowing organised players to gain share despite softer rural trends. However, prolonged monsoon conditions and delayed public capex weighed on agricultural demand, which constitutes a significant portion of industry volumes. With reservoir levels improving and government spending expected to normalise, rural demand is anticipated to recover gradually from late FY26 onward. 

 
 


A major structural shift is emerging on the supply side. India’s dependence on imported PVC, which rose sharply in recent years due to global oversupply, is expected to decline materially as large domestic capacities come online over FY27. Policy changes removing export incentives for overseas suppliers, alongside global plant shutdowns driven by unsustainable margins, are signalling the end of artificially suppressed pricing. Early indicators are already visible, with PVC prices rebounding meaningfully at the start of 2026 after an extended downturn. Greater domestic production is likely to improve supply security and reduce earnings volatility for downstream manufacturers.

 


Channel interactions highlight a bifurcated market structure. Regional brands continue to dominate agricultural and government-led projects in smaller towns due to pricing advantages and localised service networks, while organised manufacturers maintain strong positioning in urban plumbing segments where brand credibility and quality assurance remain critical. Expansion opportunities are also emerging in underpenetrated eastern markets, where supply shortages persist despite healthy demand. 

 


With pricing headwinds easing, inventory levels remaining lean, and demand drivers strengthening across both urban and rural segments, the sector’s medium-term outlook is improving. A combination of stabilising raw material costs, rising infrastructure spending, and gradual demand broadening positions the industry for more predictable growth and healthier profitability over the coming years. 


Astral – TP: ₹2,000

Astral reported healthy underlying volume growth driven by continued market share gains and resilient demand in the CPVC segment, although profitability remained affected by PVC price volatility during the quarter. With PVC prices rebounding sharply (up 16 per cent in Jan’26), margin recovery is expected to materialise going forward. The company’s increasing contribution from high-value-added products and ongoing backward integration initiatives continue to strengthen its long-term growth and margin profile. In 3QFY26, Astral delivered 17 per cent Y-o-Y volume growth; however, a 7 per cent decline in realisations due to lower PVC prices limited revenue growth to 10 per cent Y-o-Y. Ebitda margins contracted 30bp YoY owing to inventory losses, partially offset by a richer value-added product mix. We remain constructive, anticipating demand recovery, price normalisation, and improving profitability from 4QFY26 onward, with revenue/Ebitda/PAT CAGR of 16 per cent/18 per cent/ 22 per cent over FY25–28. 


Supreme Industries – TP: ₹4,800

Supreme Industries is well placed to benefit from structural growth in India’s building materials and plastic piping segments, driven by housing demand, urbanisation, and infrastructure spending. Strong brand equity, an extensive distribution network, and continuous capacity expansion support market share gains in organised plumbing and industrial applications. Improving product mix toward value-added segments enhances margin resilience despite raw material volatility. Demand tailwinds from water management, irrigation, and sanitation initiatives provide long-term volume visibility. With disciplined capital allocation, healthy balance sheet strength, and consistent return ratios, Supreme Industries offers a steady compounding opportunity aligned with India’s construction and infrastructure growth cycle.  (Disclaimer: This article is by Motilal Oswal Financial Services Research Desk. Views expressed are their own. )



Source link

YouTube
Instagram
WhatsApp